This site is intended for healthcare professionals

Breakthrough results for Jardiance confirm EMPEROR-Preserved as first and only successful trial for heart failure with preserved ejection fraction. Eli Lilly + Boehringer.

Read time: 1 mins
Last updated:29th Jul 2021
Published:7th Jul 2021
The EMPEROR-Preserved phase III trial met its primary endpoint, establishing Jardiance (empagliflozin) from Eli Lilly and Boehringer, as the first and only therapy to significantly reduce the risk of the composite of cardiovascular death or hospitalization for heart failure in adults, with or without diabetes, who live with heart failure with preserved ejection fraction (HFpEF).
Condition: Heart Failure
Type: drug
Register for free access to this exclusive healthcare learning resource

Why sign up with Medthority?

Develop your knowledge with our disease and condition focused Learning Zones

Access content from credible sources, including expert-led commentary, videos, podcasts, and webinars as well as clinical trials, treatment information and guidelines 

Personalised dashboard providing updates and recommendations for content within your areas of interest